Abstract:

Background. Significant coronary artery disease (CAD), occurring in 7-10% of patients with obstructive hypertrophic cardiomyopathy (HCM), deteriorates the clinical course and survival rates. Until recently, such combination of abnormalities was an indication for coronary artery bypass graft (CABG) and septal myoseptecmy

Aim: was to investigate the efficacy, safety and technique of combined percutaneous intervention in patients with obstructive HCM and CAD. Materials and methods. We have performed 15 combined percutaneous interventions: alcohol septal ablation (ASA) and coronary revascularization. All patients had a marked asymmetric hypertrophy of LV with outflow tract obstruction at rest, as well as severe coronary lesions (75% - 95%). During the procedure, we performed consistently ASA of target zone in charge of obstruction and coronary stenting (10 stents in LAD, 8 stents in RCA, 4 stents in LCX).

Results. Among the effects of interventions were disappearance of angina pectoris and dyspnea, reduction of the pressure gradient in the LV outflow tract and a significant decrease in the thickness of septum. No serious complications (such as MI, complete av-block, ventricular tachiarrhythmias) occured

Conclusion. These results indicate efficacy and safety of ASA combined with coronary revascularization in patients with obstructive HCM who have concomitant CAD.

References

1.    Maron B.J. Diagnosis and Managment of Hypertrophic Cardiomyopathy. Massachusetts: BlackwellFutura., 2004; 506.

2.    Romeo F., Pelliccia F., Cristofani R. et al. Hypertrophic cardiomyopathy: Is a left ventricular outflow tract gradient a major prognostic determinant? Eur. Heart J. 1990; 11: 233-240.

3.    Maron M.S., Olivotto I., Betocchi S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 2003;348: 295-303.

4.    Sigwart U. Non surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995; 346: 211-214.

5.    Knight C., Kurbaan A., Seggewiss H. et al. Non surgical septal reduction for hypertrophic obstructive   cardiomyopathy. Circulation. 1997; 95: 2075 -2081.

6.    Burry Х., Sigwart U. Alcohol ablation of interventricular septum as a method of treatment of hypertrophic obstructive cardiomyopathy. International. Journal of Interventional Cardioangiology. 2004; 4: 11-17 [In Russ].

7.    Shloydo E.A., Sukhov V.K., Kochanov I.N. Transcatheter alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Report to the XII All-Russian Congress of cardiovascular surgeons. The Bulletin of Bakoulev CCVS for Cardiovascular Surgery «Cardiovascular diseases». 2006; 7(5): 84 [In Russ].

8.    Sorajja P., Ommen S.R., Nishimura R.A. et al. Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease. Circulation. 2003; 108: 2342-2348.

9.    Cokkinos D.V., Krajcer Z., Leachman R.D. Hypertrophic Cardiomyopathy and Associated Coronary Artery Disease. Texas Heart Institute Journal. 1985; 2: 12.

10.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. J. Am. Coll,. Cardiol. 2011; 58 (25): 212-260.

11.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. J. Am Coll. Cardiol. 2011; 58(24): 44-122.

12.  Honda T., Sakamoto T., Miyamoto S. et al. Successful Coronary Stenting of the Left Anterior Descending Artery at the Branching Site of the Targeted Septal Perforator Immediately after Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy. Internal. Medicine. 2005; 44: 722-726.

13.  Nambi V., Buergler J.M., LakkisN.M. et al. Effectiveness of Percutaneous Intervention for Patients With Obstructive Hypertrophic Cardiomyopathy and Coronary Artery Disease. Am J. Cardiol. 2005; 96: 580-581.